OncoMatch

OncoMatch/Clinical Trials/NCT06415318

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Is NCT06415318 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Paclitaxel + Ifosfamide + Cisplatin & Toripalimab for penile cancer.

Phase 2RecruitingSun Yat-sen UniversityNCT06415318Data as of Jun 2026Location: China

Treatment: Paclitaxel + Ifosfamide + Cisplatin & ToripalimabPrimary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Paclitaxel + Ifosfamide + Cisplatin & Toripalimab

Cancer type

Penile Carcinoma

Disease stage

Required: Stage T4, ANY N, ANY T, N3

Clinical Stage is Locally advanced penile cancer (T4, any N stage; or any T stage, N3)

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 75
Male only

Prior therapy

Cannot have received: chemotherapy

Exception: time from last chemotherapy to relapse > 12 months

No prior chemotherapy for newly diagnosed or relapsed patients or the time from the last chemotherapy to relapse should be longer than 12 months

Cannot have received: experimental drug

Previously received any other experimental drug treatment within 4 weeks before enrollment

Lab requirements

Blood counts

hemoglobin(hb) >= 80g/l; white blood cell count >= 3.0x10^9/l; neutrophil count >= 1.5x10^9/l; platelet count >= 100x10^9/l

Liver function

ast, alt, alp <= 2.5 uln; total bilirubin <= 1.5 uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06415318 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior chemotherapy, experimental drug disqualifies patients from enrollment.

What disease stage is eligible?

Stage T4, ANY N or ANY T, N3 is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify